Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.36
(-7.69%)
SEK 3.36
(-7.69%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -79.79 Million SEK | -12.92% |
| 2022 | -70.66 Million SEK | -11.07% |
| 2021 | -63.61 Million SEK | -9.8% |
| 2020 | -57.93 Million SEK | -33.58% |
| 2019 | -43.37 Million SEK | -32.02% |
| 2018 | -32.85 Million SEK | -54.52% |
| 2017 | -21.26 Million SEK | 21.1% |
| 2016 | -26.94 Million SEK | -62.39% |
| 2015 | -16.59 Million SEK | 6.99% |
| 2014 | -17.84 Million SEK | 2.64% |
| 2013 | -18.32 Million SEK | -44.33% |
| 2012 | -12.69 Million SEK | -82.04% |
| 2011 | -6.97 Million SEK | -40.8% |
| 2010 | -4.95 Million SEK | -150.53% |
| 2009 | -1.97 Million SEK | -194.58% |
| 2008 | -671.19 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -13.59 Million SEK | -9.62% |
| 2024 Q1 | -12.39 Million SEK | 50.9% |
| 2024 Q3 | -12.96 Million SEK | 4.59% |
| 2023 Q1 | -21.28 Million SEK | -137.75% |
| 2023 Q4 | -25.25 Million SEK | -50.28% |
| 2023 Q2 | -16.45 Million SEK | 22.72% |
| 2023 FY | -79.79 Million SEK | -12.92% |
| 2023 Q3 | -16.8 Million SEK | -2.13% |
| 2022 Q4 | -8.95 Million SEK | 70.25% |
| 2022 Q1 | -13.66 Million SEK | 29.52% |
| 2022 Q2 | -16.95 Million SEK | -24.07% |
| 2022 FY | -70.66 Million SEK | -11.07% |
| 2022 Q3 | -30.09 Million SEK | -77.48% |
| 2021 Q1 | -9.46 Million SEK | 38.18% |
| 2021 Q3 | -11.87 Million SEK | 48.67% |
| 2021 Q4 | -19.39 Million SEK | -63.36% |
| 2021 FY | -63.61 Million SEK | -9.8% |
| 2021 Q2 | -23.12 Million SEK | -144.45% |
| 2020 Q4 | -15.3 Million SEK | -62.62% |
| 2020 Q2 | -12.87 Million SEK | 36.73% |
| 2020 FY | -57.93 Million SEK | -33.58% |
| 2020 Q1 | -20.34 Million SEK | -35.38% |
| 2020 Q3 | -9.41 Million SEK | 26.9% |
| 2019 Q4 | -15.03 Million SEK | -79.62% |
| 2019 FY | -43.37 Million SEK | -32.02% |
| 2019 Q3 | -8.36 Million SEK | 20.14% |
| 2019 Q1 | -9.49 Million SEK | -0.15% |
| 2019 Q2 | -10.47 Million SEK | -10.31% |
| 2018 FY | -32.85 Million SEK | -54.52% |
| 2018 Q1 | -970 Thousand SEK | 77.95% |
| 2018 Q4 | -9.48 Million SEK | -28.77% |
| 2018 Q3 | -7.36 Million SEK | 51.01% |
| 2018 Q2 | -15.03 Million SEK | -1450.0% |
| 2017 FY | -21.26 Million SEK | 21.1% |
| 2017 Q4 | -4.39 Million SEK | -19.18% |
| 2017 Q3 | -3.69 Million SEK | 32.23% |
| 2017 Q2 | -5.44 Million SEK | 29.54% |
| 2017 Q1 | -7.72 Million SEK | -61.7% |
| 2016 FY | -26.94 Million SEK | -62.39% |
| 2016 Q2 | -6.2 Million SEK | 23.7% |
| 2016 Q1 | -8.12 Million SEK | -78.41% |
| 2016 Q3 | -7.84 Million SEK | -26.47% |
| 2016 Q4 | -4.77 Million SEK | 39.05% |
| 2015 Q3 | -3.76 Million SEK | 0.58% |
| 2015 Q4 | -4.55 Million SEK | -20.91% |
| 2015 FY | -16.59 Million SEK | 6.99% |
| 2015 Q2 | -3.78 Million SEK | 15.53% |
| 2015 Q1 | -4.48 Million SEK | 48.24% |
| 2014 FY | -17.84 Million SEK | 2.64% |
| 2014 Q4 | -8.66 Million SEK | -179.0% |
| 2014 Q2 | -3.47 Million SEK | -34.2% |
| 2014 Q3 | -3.1 Million SEK | 10.73% |
| 2014 Q1 | -2.59 Million SEK | 59.07% |
| 2013 Q4 | -6.33 Million SEK | -59.03% |
| 2013 Q2 | -4.35 Million SEK | -19.3% |
| 2013 Q3 | -3.98 Million SEK | 8.57% |
| 2013 FY | -18.32 Million SEK | -44.33% |
| 2013 Q1 | -3.65 Million SEK | 3.53% |
| 2012 Q4 | -3.78 Million SEK | -23.19% |
| 2012 Q2 | -2.43 Million SEK | 28.61% |
| 2012 Q1 | -3.4 Million SEK | -39.79% |
| 2012 FY | -12.69 Million SEK | -82.04% |
| 2012 Q3 | -3.07 Million SEK | -26.4% |
| 2011 Q3 | -1.22 Million SEK | 25.63% |
| 2011 Q2 | -1.65 Million SEK | 0.05% |
| 2011 Q1 | -1.65 Million SEK | -48.28% |
| 2011 Q4 | -2.43 Million SEK | -98.27% |
| 2011 FY | -6.97 Million SEK | -40.8% |
| 2010 Q2 | -879.93 Thousand SEK | 52.92% |
| 2010 FY | -4.95 Million SEK | -150.53% |
| 2010 Q3 | -1.08 Million SEK | -23.85% |
| 2010 Q1 | -1.86 Million SEK | -467.03% |
| 2010 Q4 | -1.11 Million SEK | -2.3% |
| 2009 Q2 | -402.23 Thousand SEK | 52.82% |
| 2009 Q1 | -852.6 Thousand SEK | -279.54% |
| 2009 FY | -1.97 Million SEK | -194.58% |
| 2009 Q4 | -329.61 Thousand SEK | 16.08% |
| 2009 Q3 | -392.74 Thousand SEK | 2.36% |
| 2008 FY | -671.19 Thousand SEK | 0.0% |
| 2008 Q4 | 474.88 Thousand SEK | 220.34% |
| 2008 Q3 | -394.63 Thousand SEK | 15.75% |
| 2008 Q2 | -468.43 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | -2.509% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 177.094% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 177.094% |
| Arcoma AB | 2.56 Million SEK | 3212.012% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 42.339% |
| BICO Group AB (publ) | -835.7 Million SEK | 90.452% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 419.462% |
| CellaVision AB (publ) | 130.3 Million SEK | 161.233% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -173.385% |
| C-Rad AB (publ) | 35.52 Million SEK | 324.583% |
| Duearity AB (publ) | -26.19 Million SEK | -204.666% |
| Dignitana AB (publ) | -17.36 Million SEK | -359.552% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 15.831% |
| Getinge AB (publ) | 2.41 Billion SEK | 103.308% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | -17.38% |
| Iconovo AB (publ) | -45.89 Million SEK | -73.862% |
| Integrum AB (publ) | 4.03 Million SEK | 2078.734% |
| Luxbright AB (publ) | -25.37 Million SEK | -214.45% |
| Mentice AB (publ) | -2.81 Million SEK | -2732.517% |
| OssDsign AB (publ) | -130.49 Million SEK | 38.853% |
| Paxman AB (publ) | 8.33 Million SEK | 1057.887% |
| Promimic AB (publ) | -9.22 Million SEK | -765.235% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 50.116% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -43.55% |
| ScandiDos AB (publ) | -14.64 Million SEK | -444.767% |
| Sectra AB (publ) | 428.38 Million SEK | 118.626% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -33.852% |
| Senzime AB (publ) | -134.14 Million SEK | 40.52% |
| SpectraCure AB (publ) | -20.44 Million SEK | -290.353% |
| Stille AB | 26.64 Million SEK | 399.452% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 97.928% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 186.9% |